Thomas Trimarchi's most recent trade in BridgeBio Pharma Inc was a trade of 22,781 Common Stock done at an average price of $79.9 . Disclosure was reported to the exchange on Aug. 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.86 per share. | 16 Aug 2026 | 22,781 | 336,529 (0%) | 0% | 79.9 | 1,819,291 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.13 per share. | 16 May 2026 | 22,781 | 372,845 (0%) | 0% | 66.1 | 1,506,508 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 64.82 per share. | 16 May 2026 | 10,456 | 362,389 (0%) | 0% | 64.8 | 677,707 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 65.95 per share. | 16 May 2026 | 3,195 | 359,194 (0%) | 0% | 66.0 | 210,712 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2026 | 59,041 | 395,626 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.25 per share. | 16 Feb 2026 | 18,819 | 350,185 (0%) | 0% | 75.3 | 1,416,130 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 74.71 per share. | 16 Feb 2026 | 13,400 | 336,785 (0%) | 0% | 74.7 | 1,001,071 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 75.38 per share. | 16 Feb 2026 | 200 | 336,585 (0%) | 0% | 75.4 | 15,076 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.15 per share. | 12 Dec 2025 | 13,826 | 369,004 (0%) | 0% | 75.2 | 1,039,024 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.39 per share. | 16 Nov 2025 | 21,317 | 399,764 (0%) | 0% | 66.4 | 1,415,236 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 66.19 per share. | 16 Nov 2025 | 9,978 | 389,786 (0%) | 0% | 66.2 | 660,467 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 66.84 per share. | 16 Nov 2025 | 6,956 | 382,830 (0%) | 0% | 66.8 | 464,938 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 49.48 per share. | 21 Aug 2025 | 42,237 | 421,081 (0%) | 0% | 49.5 | 2,090,081 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.32 per share. | 16 Aug 2025 | 21,317 | 480,671 (0%) | 0% | 51.3 | 1,093,988 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 50.14 per share. | 16 Aug 2025 | 15,380 | 465,291 (0%) | 0% | 50.1 | 771,210 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Sale of securities on an exchange or to another person at price $ 50.94 per share. | 16 Aug 2025 | 1,973 | 463,318 (0%) | 0% | 50.9 | 100,512 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 16 May 2025 | 21,317 | 501,988 (0%) | 0% | 33.8 | 721,367 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2025 | 109,100 | 523,305 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.90 per share. | 16 Feb 2025 | 13,782 | 414,205 (0%) | 0% | 34.9 | 480,992 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 50,000 | 427,987 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 16 Nov 2024 | 17,936 | 377,987 (0%) | 0% | 23.7 | 425,442 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.40 per share. | 16 Aug 2024 | 17,936 | 395,923 (0%) | 0% | 24.4 | 437,638 | Common Stock |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 19,003 | 413,859 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Dr. Thomas Trimarchi, PhD | President and COO | 06 Aug 2024 | 3,160 | 3,160 | - | - | Stock Option (Right to Buy) |